Healthcare Affordability
Expert articles and analysis related to healthcare affordability.
AI Summary — Last 7 Days
The Trump administration’s affordability push is increasingly translating into payment-model and Medicaid financing pressure: CMS is advancing a Medicaid drug payment model aimed at lowering drug costs while also pursuing state-directed payment cuts, creating a direct tension between federal savings goals and provider/state revenue strategies for VBC infrastructure. At the same time, reconciliation-driven Medicaid changes and the new $50B Rural Health Transformation Program are reshaping population health risk—states may receive transition funding, but potential coverage losses and rural access strain could undercut ACO and Medicaid managed care efforts to manage total cost of care (KFF rural health program analysis). Evidence scrutiny is also tightening around “value” claims, with Mathematica pointing to Medicare joint replacement savings opportunities and PHTI questioning whether virtual kidney care lowers costs, signaling that purchasers and CMS will expect stronger proof before rewarding care-transformation vendors or specialty models (Mathematica joint replacement analysis).
Related Articles
Klomp, Warren spar over MFN deal contracts
Top HHS official Chris Klomp had a relatively mild nomination hearing with senators on Tuesday, but he sparred with Sen. Elizabeth Warren (D-MA) over voluntary agreements with large drugmakers and wha...
Survey: Adults With Multiple or Complex Health Conditions Face Significant Challenges with Health Costs and Commonly Struggle to Access Care
Adults with multiple or complex health conditions, who already face unique physical and mental challenges, commonly struggle to pay their medical bills and access needed care and medication—challenges...
Health Care Access and Affordability for Adults with Multiple or Complex Health Conditions: A Snapshot of Patient Experiences
Significant shares of adults with multiple or complex health conditions, including cancer, lung disease, diabetes, cardiovascular disease, and mental health conditions say they struggle to pay their m...
J&J adds 340B claims data requirements amid growing manufacturer restrictions
Johnson & Johnson joined the list of drug manufacturers requiring providers to submit claims data on in-house pharmacy drugs as a condition of receiving discounts in the 340B Drug Pricing Program. Hos...
Comparison of Recent 340B Bills
Comparison of Recent 340B Bills American Hospital Association
Medicare's new drug pricing plan could backfire, driving up prices worldwide, study warns
Health Insurance Protects Consumers from the High Cost of Medical Care
Health Insurance Protects Consumers from the High Cost of Medical Care AHIP
The US experiments with international reference pricing for prescription drugs
The US experiments with international reference pricing for prescription drugs The Lancet
The US experiments with international reference pricing for prescription drugs
The US experiments with international reference pricing for prescription drugs The Lancet
New advocacy resources available on price transparency, 340B
New advocacy resources available on price transparency, 340B American Hospital Association